37 articles with Centogene
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
Research Fellow from German Research Center for Artificial Intelligence to lead team driving solutions for pharmaceutical partners
Combining genetic and biochemical testing to provide the most comprehensive screening for rare metabolic conditions
CENTOGENE announces the appointment of Dr. Flemming Ornskov to the Supervisory Board as Non-Executive Chairman
CENTOGENE announced that Dr. Flemming Ornskov has been appointed to the Supervisory Board and has been elected Non-Executive Chairman. His appointment is effective April 1, 2019.
Agreement focused on identification of patients with Duchenne muscular dystrophy (DMD)
CENTOGENE Develops New Validation Framework to Optimize Specificity and Sensitivity in Whole Exome Sequencing-Based Diagnostics
Since NGS introduces a relevant number of false positives and false negatives, CENTOGENE has determined how to optimize the use of orthogonal Sanger sequencing of variants in parallel when looking at borderline cases.
Driving Pharmaceutical Partnerships and Accelerating Orphan Drug Development
CENTOGENE’s state-of-the-art genetic laboratory facilities in Rostock, Germany awarded accreditation for the fourth year
2018 highlights include expansion to U.S., new partnerships with leading pharmaceutical companies, and growth of diagnostic testing portfolio for rare diseases - driving momentum into 2019
CENTOGENE to perform epidemiology study in Alpha Mannosidosis to support Chiesi’s drug discovery and development
CENTOGENE today announced the launch of CentoPharma 1.0, the world’s first CE labeled platform for targeted patient cohort identification.
The College of American Pathologists has awarded CENTOGENE AG accreditation to the ISO15189 standard under the CAP 15189SM Accreditation Program.
CENTOGENE today announced updates to CentoMD®, the world’s largest genetic mutation database of rare diseases.
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
CENTOGENE Further Expands Executive Team, Appoints Oved Amitay as Chief Business Officer; Increases Focus on Pharma Partnerships
CENTOGENE, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, today announced the appointment of Oved Amitay as Chief Business Officer.
CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical TrialsCENTOGENE to conduct a targeted global identification and recruitment campaign to support Denali´s LRRK2 inhibitor program
CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2 mutation carrier Parkinson’s disease (“PD”) patients.
CENTOGENE and Evotec Sign Global Strategic Partnership on Drug Discovery Projects in Rare Genetic Diseases
Joint Drug Discovery Projects Combine CENTOGENE’s Patient Access and Biomarker Expertise with Evotec’s Leading iPSC Platform
Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform.
CENTOGENE Partners with the Universities of Greifswald and Rostock to Develop Fast-Tracked Diagnostic Workflow for Personalized Immune-based Therapies for Colon and Pancreatic Tumors
CENTOGENE is committed to developing a fast-track diagnostic workflow which lays the groundwork for individualized vaccination therapy in cancer.
There are several recent announcements of German companies opening laboratories in the U.S.